Effect of bortezomib on CCL2/MCP-1 and CCL5/RANTES secretion by DCs
. | None . | LPS . | LPS + bortezomib 1 ng/mL . | LPS + bortezomib 10 ng/mL . | LPS + bortezomib 20 ng/mL . |
|---|---|---|---|---|---|
| CCL2/MCP1 | 1063.9 | > 2000 | 836.2 | 798.9 | 719.2 |
| CCL5/RANTES | 8.5 | > 2000 | 422 | 50.2 | 42.3 |
. | None . | LPS . | LPS + bortezomib 1 ng/mL . | LPS + bortezomib 10 ng/mL . | LPS + bortezomib 20 ng/mL . |
|---|---|---|---|---|---|
| CCL2/MCP1 | 1063.9 | > 2000 | 836.2 | 798.9 | 719.2 |
| CCL5/RANTES | 8.5 | > 2000 | 422 | 50.2 | 42.3 |
Adherent monocytes were cultured with GM-CSF and IL-4 for 6 days. Subsequently, cells were treated for 24 hours with bortezomib at the indicated concentrations. LPS was present in the culture medium during the last 16 hours. CCL2 and CCL5 secretions (in pg/mL) were determined in the supernatant using commercially available ELISAs.